Glucarpidase
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Glucarpidase: From Methotrexate Toxicity to Diabetic Cataract
One-Sentence Summary
Glucarpidase (carboxypeptidase G2) is a recombinant bacterial enzyme used to rapidly clear toxic plasma methotrexate concentrations in patients with impaired renal clearance. The TxGNN model predicts it may be effective for Diabetic Cataract, but currently no clinical trials and no published literature support this direction, and the model’s own mechanistic rationale flags the prediction as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Methotrexate toxicity (rescue therapy for elevated plasma methotrexate levels) — not derived from a formal license record in this evidence pack |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Glucarpidase’s only established pharmacological action is hydrolyzing the glutamate residue on folate/methotrexate molecules to rapidly eliminate circulating methotrexate — it is used as an emergency detoxification enzyme, not a disease-modifying therapeutic. This action has no known relationship to lens protein metabolism, the polyol (aldose reductase) pathway, oxidative stress, or any other mechanism implicated in diabetic cataract formation.
The evidence pack’s own mechanistic analysis for this candidate explicitly states there is no known biological pathway connecting glucarpidase to cataract pathophysiology, and suggests the prediction likely reflects a knowledge-graph embedding artifact (“false positive”) caused by data sparsity for this rare indication pairing, rather than a genuine pharmacological signal. This same “no mechanistic link” conclusion is repeated across all 10 top-ranked predicted indications for this drug (diabetic retinopathy, tetanic cataract, senile cataract, etc.), all clustered at similar TxGNN scores — a pattern consistent with a systematic embedding-space artifact rather than a specific, credible signal for any one disease.
Given this, the high TxGNN score should be interpreted as a statistical association within the model’s latent space, not as evidence of therapeutic plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Glucarpidase currently holds no EU marketing authorizations (market status: Not marketed, 0 licenses on file in this evidence pack).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA label warnings/contraindications and formal MOA data are flagged as blocking/high-severity data gaps in this evidence pack — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: There is no mechanistic rationale, no clinical trial evidence, and no published literature connecting glucarpidase to diabetic cataract or any of its other top-ranked predicted indications. The evidence pack’s own analysis identifies this as a likely false-positive prediction driven by embedding-space sparsity rather than genuine pharmacology. Combined with the drug having no EU marketing presence and missing safety documentation, this candidate does not meet the bar to proceed.
To proceed, the following is needed:
- TFDA label (仿單) warnings and contraindications — currently a blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank API — currently a high-severity data gap (DG002)
- Independent pharmacological or preclinical rationale linking glucarpidase to any diabetic ophthalmic pathway, before further evidence collection is warranted
- Re-evaluation of whether this candidate should remain in the pipeline given the model’s own rationale disputing biological plausibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.